$VRTX
-
Markets
Vertex Pharmaceuticals Faces Challenges In Q1 2025 Continued Innovation
$VRTX Vertex Pharmaceuticals (NASDAQ:VRTX) ,the Boston-based biotechnology firm, reported quarterly earnings of $4.06 per share, which fell short of the…
Read More » -
Markets
Vertex Pharmaceuticals Unveils Groundbreaking Non-opioid Pain Treatment, JOURNAVX™
$VRTX In a significant advancement for pain management, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced the FDA approval of JOURNAVX™ (suzetrigine), marking…
Read More » -
Markets
Vertex Pharmaceuticals Q1 2024 Earnings: Surpasses Revenue Expectations With Strategic Expansions
$VRTX Vertex Pharmaceuticals, a prominent global biotechnology firm known for its innovative drug developments for serious diseases, has recently announced…
Read More »